Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.46 | N/A | +5.67% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.46 | N/A | +5.67% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism regarding their clinical developments. They acknowledged the competitive landscape but emphasized their commitment to innovation.
Management highlighted ongoing progress in clinical trials.
They expressed confidence in their pipeline but noted challenges ahead.
PTC Therapeutics reported a narrower-than-expected loss per share, which led to a positive stock reaction, rising 1.65%. The company did not provide revenue figures or future guidance, leaving investors to focus on the progress of their clinical trials. Management's cautious optimism suggests they are aware of the challenges but are committed to advancing their pipeline.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NUTRIEN LTD
May 7, 2018